Q-omics provides the consensus-scored JMJD7-PLA2G4B profile across patient tissues and cancer cell-line models. JMJD7-PLA2G4B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, JMJD7-PLA2G4B is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, JMJD7-PLA2G4B RNA expression shows 20,464 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where JMJD7-PLA2G4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JMJD7-PLA2G4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JMJD7-PLA2G4B survival associations across molecular data types. JMJD7-PLA2G4B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JMJD7-PLA2G4B RNA expression–survival associations across cancer types. High JMJD7-PLA2G4B expression shows unfavorable associations in KIRC, COAD and UVM, but favorable associations in SCLC, HNSC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for JMJD7-PLA2G4B RNA expression.
This table summarizes JMJD7-PLA2G4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for JMJD7-PLA2G4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JMJD7-PLA2G4B shows lower tumor expression in BRCA and LUAD and higher tumor expression in COAD, CHOL, READ and LIHC. The COAD box plot shows higher JMJD7-PLA2G4B RNA expression in tumor versus normal tissue (log2 FC = +0.488, t-test p < 0.001).
This table shows molecular features associated with JMJD7-PLA2G4B in patient tissues and cancer cell lines. In patient samples, JMJD7-PLA2G4B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, JMJD7-PLA2G4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
